Protagonist Therapeutics Inc
PTGX
查看详细走势图
84.490USD
+3.820+4.74%
收盘 02/06, 16:00（美东）报价延迟15分钟
5.28B总市值
108.79市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+4.74%
5天
+3.29%
1月
+5.35%
6月
+65.44%
今年开始到现在
-3.26%
1年
+117.31%
查看详细走势图
TradingKey Protagonist Therapeutics Inc股票评分
单位: USD 更新时间: 2026-02-06操作建议
Protagonist Therapeutics Inc当前公司基本面数据相对非常健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名21/392位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价100.54。中期看，股价处于平稳状态。近一个月，市场表现较强，技术面和基本面综合得分较高，较强的走势得到基本面和技术面的印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
Protagonist Therapeutics Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
看好
Protagonist Therapeutics Inc亮点
亮点风险
Protagonist Therapeutics, Inc. is a biopharmaceutical company focused on peptide therapeutics. The Company’s clinical programs fall into two categories of diseases: hematology and blood disorders, and inflammatory and immunomodulatory diseases. Its two peptides derived from its proprietary discovery technology platform, rusfertide and icotrokinra, are in advanced Phase III clinical development. Its rusfertide (PTG-300) is an injectable hepcidin mimetic in development for the potential treatment of polycythemia vera (PV) and other blood disorders. Icotrokinra, an orally delivered IL-23R specific antagonist for the potential treatment of psoriasis, psoriatic arthritis (PsA), ulcerative colitis and inflammatory bowel disease (IBD) indications. The Company also has a pre-clinical stage oral drug discovery program addressing clinically and commercially validated targets, including the IL-17 oral peptide antagonist PN-881, an oral hepcidin program, and an oral obesity program.
业绩高增长
公司营业收入稳步增长，连续3年增长1534.37%
业绩转盈
公司业绩转盈，最新年度盈利美元
估值高估
公司最新PE估值108.79，处于3年历史高位
机构减仓
最新机构持股74.52M股，环比减少6.60%
CI 精选加拿大股票基金持仓
明星投资者CI 精选加拿大股票基金持仓，最新持仓市值163.00
分析师目标
根据
13
位分析师
买入
评级
100.538
目标均价
+18.99%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Protagonist Therapeutics Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Protagonist Therapeutics Inc简介
Protagonist Therapeutics, Inc. is a biopharmaceutical company focused on peptide therapeutics. The Company’s clinical programs fall into two categories of diseases: hematology and blood disorders, and inflammatory and immunomodulatory diseases. Its two peptides derived from its proprietary discovery technology platform, rusfertide and icotrokinra, are in advanced Phase III clinical development. Its rusfertide (PTG-300) is an injectable hepcidin mimetic in development for the potential treatment of polycythemia vera (PV) and other blood disorders. Icotrokinra, an orally delivered IL-23R specific antagonist for the potential treatment of psoriasis, psoriatic arthritis (PsA), ulcerative colitis and inflammatory bowel disease (IBD) indications. The Company also has a pre-clinical stage oral drug discovery program addressing clinically and commercially validated targets, including the IL-17 oral peptide antagonist PN-881, an oral hepcidin program, and an oral obesity program.
公司代码PTGX
公司Protagonist Therapeutics Inc
CEOPatel (Dinesh V)
网址https://www.protagonist-inc.com/
相关品种
